ArticleFoods (Basel, Switzerland)2025
Preventive and Therapeutic Effects of Sericin-Derived Oligopeptides (SDOs) from Yellow Silk Cocoons on Blood Pressure Lowering in L-NAME-Induced Hypertensive Rats.
Article in Foods (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Distinct and Overlapping Neuroprotective Efficacy of Silk Lutein and Sericin-Derived Oligopeptides from Yellow Silk Cocoons in Rodent Models of AInternational journal of molecular sciences · 2026Article
- Consumption of Sericin Enhances the Bioavailability and Metabolic Efficacy of Chromium Picolinate in Rats.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Our previous research has shown that SDOs derived from yellow silk cocoons have hypotensive effects on rats in chronic toxicity testing. This study investigated the potential preventative and therapeutic benefits of SDOs on hypertensive rats induced by L-NAME. The experiment involved nine rat groups: (1) normal control, (2) normal + 200 mg kg-1 BW SDOs, (3) hypertensive (HT) control, (4) HT + 50 mg kg-1 BW SDOs, (5) HT + 100 mg kg-1 BW SDOs, (6) HT + 200 mg kg-1 BW SDOs, (7) HT + enalapril (Ena), (8) HT + soy protein isolate (SPI), and (9) HT + bovine serum albumin (BSA). In the preventative approach, rats received 40 mg kg-1 of L-NAME with the studied substances during the four-week investigation. SDOs given at doses of 100 and 200 mg kg-1 BW demonstrated a significant decrease in systolic blood pressure (SBP) without affecting heart rate (HR). In therapeutic studies, 40 mg kg-1 BW of L-NAME increased SBP in the experimental groups over the first four weeks, resulting in mean SBP values above 150 mmHg. Administering 100 and 200 mg kg-1 BW SDOs and 100 mg kg-1 BW SPI significantly reduced SBP. However, SDOs at 200 mg kg-1 BW exhibited SBP closer to the enalapril group. In functional vascular tests, rats given SDOs at a dose of 200 mg kg-1 BW had the highest relaxation and lowest contraction percentages, like the normal control groups. The research found that SDOs may inhibit and manage hypertension in both healthy and hypertensive rats by safeguarding endothelial cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.